Abstract:Doxorubicin (Dox) is a broad-spectrum antitumor drug used for the treatment of many types of malignant tumors. Although it possesses powerful antitumor activity, its clinical application is seriously encumbered by its unselective distribution and systemic toxicities, particularly myocardial toxicity. Thus, it is imperative to modify Dox to decrease its systemic toxicities and improve its therapeutic index. In the present study, we adopted a novel type of monomethoxy poly(ethylene glycol)-poly(ε-caprolactone) (MPEG-PCL) micelles to encapsulate Dox to prepare Dox-loaded MPEG-PCL (Dox/MPEG-PCL) nanoparticles by a controllable self-assembly process. The cellular uptake efficiency and cell proliferation inhibition of the Dox/MPEG-PCL nanoparticles were examined. The antitumor activity of the Dox/MPEG-PCL nanoparticles was tested on a multiple pulmonary metastasis model of melanoma on C57BL/6 mice. Systemic toxicities and survival time were compared between the mice treated with the Dox/MPEG-PCL nanoparticles and free Dox. The potential myocardial toxicity of the Dox/MPEG-PCL nanoparticles was investigated using a prolonged observation period. Encapsulation of Dox in MPEG-PCL nanoparticles significantly improved the cellular uptake and cell proliferation inhibition of Dox in vivo. Intravenous injection of Dox/MPEG-PCL nanoparticles obtained significant inhibition of the growth and metastasis of melanoma in the lung and prolonged survival time compared with free Dox (P<0.05). The Dox/MPEG-PCL nanoparticles did not show obvious additional systemic toxicities compared with free Dox during the treatment time. During the prolonged observation period, obvious decreased cardiac toxicity was observed in the Dox/MPEG-PCL nanoparticle-treated mice compared with that observed in the free Dox-treated mice. These results indicated that encapsulating Dox with MPEG-PCL micelles could significantly promote its antitumor activity and reduce its toxicity to the myocardium.

PEG-PLGA Nanoparticles Entrapping Doxorubicin Reduced Doxorubicin-Induced Cardiotoxicity in Rats

Novel PLGA-based Nanoformulation Decreases Doxorubicin-Induced Cardiotoxicity

A Novel Self-Assembly Albumin Nanocarrier for Reducing Doxorubicin-Mediated Cardiotoxicity.

Ginsenoside Rg3 micelles mitigate doxorubicin-induced cardiotoxicity and enhance its anticancer efficacy

Improved Antitumor Activity and Reduced Myocardial Toxicity of Doxorubicin Encapsulated in MPEG-PCL Nanoparticles.

Biotin-Conjugated Multilayer Poly [D,l-Lactide-co-glycolide]-lecithin-polyethylene Glycol Nanoparticles for Targeted Delivery of Doxorubicin.

Reexamining the effects of drug loading on the in vivo performance of PEGylated liposomal doxorubicin

PEG-oligocholic acid telodendrimer micelles for the targeted delivery of doxorubicin to B-cell lymphoma

PEGylated-PLGA Nanoparticles Coated with Ph-Responsive Tannic Acid-Fe(III) Complexes for Reduced Premature Doxorubicin Release and Enhanced Targeting in Breast Cancer.

Impact of PEG Content on Doxorubicin Release from PLGA-co-PEG Nanoparticles

Enhanced Activity of Doxorubicin in Drug Resistant A549 Tumor Cells by Encapsulation of P-Glycoprotein Inhibitor in Plga-Based Nanovectors

Protective Effects of Psoralen Polymer Lipid Nanoparticles on Doxorubicin - Induced Myocardial Toxicity

An Improved D-α-tocopherol-based Nanocarrier for Targeted Delivery of Doxorubicin with Reversal of Multidrug Resistance.

Acid-sensitive PEG-removable Nanoscale Liposomes for Delivery of Doxorubicin in A549/ADR Therapy

Cardiac Reprogramming with Drug Resistance Alleviates Doxorubicin-induced Cardiotoxicity in Mice and Pigs

Regulated pH-Responsive Polymeric Micelles for Doxorubicin Delivery to the Nucleus of Liver Cancer Cells.

Nanomicelles Based on a Boronate Ester-Linked Diblock Copolymer As the Carrier of Doxorubicin with Enhanced Cellular Uptake.

Uptake and Release Profiles of PEGylated Liposomal Doxorubicin Nanoparticles: A Comprehensive Picture Based on Separate Determination of Encapsulated and Total Drug Concentrations in Tissues of Tumor-Bearing Mice.

Self-Assembling Doxorubicin Prodrug Forming Nanoparticles and Effectively Reversing Drug Resistance in Vitro and in Vivo

Targeted delivery by pH-responsive mPEG-S-PBLG micelles significantly enhances the anti-tumor efficacy of doxorubicin with reduced cardiotoxicity

Smart doxorubicin nanoparticles with high drug payload for enhanced chemotherapy against drug resistance and cancer diagnosis